SecBot SecBot

BLSM

BlossomHill Therapeutics, Inc.
Nasdaq· CIK 0001839970 Biotech & Drug Discovery
$15.76 −0.63 (−3.84%)
Oct 27 4:00 PM ET · prev $16.39
Market cap
$465.0M
Small cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$35.00
+122% · range $30.00–40.00
Since first trade
−1.5%
from $16.00 · Aug 7
30 days
−26.1%
from $21.34
Range since listing
$13.94–26.82
−41% from high · low Oct 16
Avg volume 20D
166.7K
shares / day
Short interest
485.0K
≈1.5% of shares · +2.4%
Days to cover
2.9
at average volume
Insider net
+$25.2M
6 buyers · 0 sellers · 12 mo
Filing reports
15
analyzed by SecBot
SecBot read MIXED 16 reports · 90 days
Balance 2 bearish · 4 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 14/16
Strongest BEARISH BlossomHill Therapeutics reported Q2 2026 EPS of -$8.75, a 874% miss vs consensus of -$0.90, with zero…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    6 insiders bought $25.2M at an average $16.00. No open-market sales.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +2.4% to 485.0K shares. 2.9 days to cover, ≈1.5% of shares.

  • TrendDOWNTREND

    17% below its 50-day average.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy4Buy6Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +122%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Sep 21, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Sep 21, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 1, 2026LifeSci Capital
INITIATE
INITIATEOutperform
Sep 1, 2026Leerink Partners
INITIATE
INITIATEOutperform
Sep 1, 2026JP Morgan
INITIATE
INITIATEOverweight
Sep 1, 2026Guggenheim
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 28, 2026
Earnings
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting…
Sep 18, 2026
Earnings
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering
Sep 3, 2026
Press release
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an…
Aug 7, 2026
Listing
New Listing: BLSM — BlossomHill Therapeutics, Inc. - Common Stock
Listed on exchange Q
Aug 6, 2026
Offering
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical…

Insider ledger

Form 4
$25.2M
bought · 6 insiders
$0
sold · 0 insiders
−1.5%
vs their $16.00 cost
DateInsiderTypeValue
Aug 10, 2026
Schmid John P.
Director
BUY$96.0K
Aug 10, 2026
Agrawal Sundeep
Director
CONVERT578,524 sh
Aug 10, 2026
Li Yishan
Executive Chairman
CONVERT113,435 sh
Aug 10, 2026
Agrawal Sundeep
Director
CONVERT578,524 sh
Aug 10, 2026
Li Yishan
Executive Chairman
CONVERT124,779 sh
Aug 10, 2026
Keyes Jason A
Chief Financial Officer
BUY$11.2K
Aug 10, 2026
Chen Bihua
Director
CONVERT1,599,993 sh
Aug 10, 2026
Chen Bihua
Director
CONVERT1,701,541 sh

Earnings setup

Estimates
−$0.90
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.90-$0.92–-$0.88—$0.00
Next Q-$1.01-$1.08–-$0.94—$0.00
Current FY-$5.10-$6.33–-$3.86—$0.00
Next FY-$3.95-$4.14–-$3.77—$0.00

Short side

FINRA· Oct 15, 2026
484,963
shares short
+2.4%
vs prior settlement
2.9
days to cover
≈1.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 SEC
BlossomHill Therapeutics reported Q2 2026 EPS of -$8.75, a 874% miss vs consensus of -$0.90, with zero revenue. The…
PRESS-RELEASE — Impact 7/10
Sep 28, 2026 Earnings
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across m
Sep 18, 2026 SEC
BlossomHill Therapeutics reported Q2 2026 net loss of $23.8M ($-8.75/share), significantly wider than the $-0.77…
8-K — Impact 6/10
Sep 18, 2026 SEC
BlossomHill Therapeutics reported Q2 2026 net loss of $23.8M ($-8.75/share), far exceeding the consensus estimate of…
PRESS-RELEASE — Impact 5/10
Aug 10, 2026 Insider
Schmid John P. bought 6,000 shares
Director @ $16.00 ($96.0K)
Aug 10, 2026 Insider
Agrawal Sundeep disposed of 578,524 shares
Director
Aug 10, 2026 Insider
Li Yishan disposed of 113,435 shares
Executive Chairman
Aug 6, 2026 Press
BlossomHill Therapeutics priced its upsized IPO of 9,375,000 shares at $16.00/share, raising $150.0 million in gross…
Impact 6/10

SecBot reports

15 filings · 1 press release · 3 bullish · 2 bearish · 10 neutral
All BLSM filing & press-release reports (16)